View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
December 21, 2021updated 07 Jan 2022 6:13am

Coronavirus company news summary – Moderna Covid-19 booster effective against Omicron – Everest-Providence’s vaccine gets support to join WHO STV clinical trial

By Kezia Parkins

Moderna has said that laboratory testing has shown that a booster shot of its Covid-19 vaccine can offer protection against the Omicron variant. A two-dose regimen generated low-levels of antibodies, while a 50-microgram booster dose increased neutralising antibodies by 37-fold. The company is also working to develop an Omicron-specific vaccine. The trials are expected to commence early next year, reported Reuters. 

Everest Medicines and Providence Therapeutics have announced that their Covid-19 vaccine PTX-COVID19-B has secured a recommendation to become a part of WHO Solidarity Trial Vaccines (STV) clinical trial. The vaccine received the endorsement by an independent advisory group. The STV trials are designed to expedite the evaluation of potential new vaccine candidates. The PTX-COVID19-B is an mRNA vaccine currently under Phase II development.

Russia’s Gamaleya Institute is expected to submit its latest clinical data of the Sputnik V Covid-19 vaccine by the end of this month, a WHO official told Reuters. The vaccine was approved by Russia last year. However, it is yet to receive a green light from WHO or the European Medicines Agency (EMA). Gamaleya is seeking WHO emergency use listing and is expected to submit data and application in two parts. The process is slated to complete by the end of January next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology